Ortec to Participate in Tissue Engineering Skin Roundtable At SAWC Annual Meeting; Cambrex and Ortec to Exhibit OrCel at SAWC.

NEW YORK -- Ortec International, Inc., (ORTN) announced that its President and Chief Operating Officer, Costa Papastephanou, Ph.D., was invited to participate in a session entitled "Tissue-Engineered Skin" at the upcoming annual meeting of the Symposium of Advanced Wound Care (SAWC).

The panel discussion will be moderated by Dr. Terry Treadwell, Medical Director at the Institute for Advanced Wound Care at Jackson Hospital in Montgomery, Alabama. Joining Dr. Papastephanou will be Dr. William Marston, assistant professor in vascular surgery at University of North Carolina-Chapel Hill. The panel is expected to discuss the mechanisms of action, clinical expectations, and potential indications of clinical use of tissue engineered products, including OrCel(R). The session will take place on Sunday, April 24th from 2:00 p.m. - 7 p.m. at the San Diego Convention Center in San Diego, California.

Ortec and its U.S. Marketing Partner, Cambrex, (NYSE:CBM) will feature OrCel(R) and information on its clinical and regulatory status and related scientific background at an exhibit at the SAWC. The Ortec and Cambrex exhibit will be located at Booth #104.

About Ortec International, Inc.

Ortec International, Inc., (ORTN), is a tissue-engineering company involved in the commercialization of a proprietary and patented technology to stimulate the repair and regeneration of human tissue. Ortec's current focus is the application of its OrCel(R) (Bilayered Cellular Matrix) to heal chronic and acute wounds. OrCel(R) is composed of a collagen sponge seeded with allogeneic epidermal and dermal cells. These cells secrete growth factors and cytokines normally found in acute human wounds and are believed to have a beneficial role in promoting tissue repair. In addition to having received FDA approvals for the treatment of Epidermolysis Bullosa and donor sites in burn patients, a pivotal clinical trial has been completed for venous ulcers, and a PMA has been filed. In addition, the FDA has granted Ortec approval to initiate a pivotal trial in diabetic foot ulcers. Ortec believes that its platform technology may extend to the regeneration of other human tissue such as tendons, ligaments, cartilage, bone, muscle and blood vessels. For more information, visit Ortec's website at http://www.ortecinternational.com.

This news release may contain "forward-looking statements" for the purposes of the United States Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3B-6 under The Exchange Act, without limitation, statements regarding expected FDA approvals, clinical trial results, product performance, expectations with respect to sales, gross margins, research and development expenditures, earnings per share, capital expenditures, collaborations, or other expansion opportunities. These statements may be identified by words such as "expects", "anticipates", "intends", "estimates", "believes" or similar expressions in connection with any discussion of future financial and operating performance. The forward-looking statements contained herein involve risks and uncertainties that may cause results to differ materially from the Company's expectations including but not limited to, global economic trends, competitive pricing or product developments, government legislation and/or regulations, technology, manufacturing, legal and patent issues, suppliers, capital availability, personnel changes, cancellation or delays in renewal of contracts, and lack of suitable raw materials or packaging materials. Investors are cautioned to review risk factors in the Company's filings with the United States Securities and Exchange Commission.